Table 3 IC50 values and AF calculated for doxorubicin, when combined with the Betti-base, tylosin or TBN

From: In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin

 

Transfected cells

Parental cells

 

IC 50 μ m ± s.e.

AF

IC50 μ m ± s.e.

AF

Betti-base IC10

0.2±0.3

9.2

0.01±0.2

1.7

Betti-base IC10/10

2.5±0.5

0.7

0.02±0.2

1.0

Tylosin IC10

0.2±0.1

7.4

0.02±0.3

1.1

Tylosin IC10/10

0.2±0.1

7.4

0.02±0.2

0.6

TBN IC10

0.01±0.1

134.1

0.008±0.1

2.8

TBN IC10/10

0.2±0.1

10.5

0.05±0.02

0.4

  1. Abbreviations: AF=antiproliferative factors; TBN=N-tylosil-1-α-amino-(3-bromophenyl)-methyl-2-naphthol.
  2. Non-resistant (parental cells) and human MDR1 gene-transfected (transfected cells) L5178 mouse lymphoma cells were treated in cell culture plates at 37°C for 72 h with different concentrations of doxorubicin, and co-incubated with the IC10 or a 10-fold lower concentration (IC10/10) of the Betti-base, tylosin or TBN. At the end of the incubation period, the relative cell density was determined using an MTT assay and optical density reading. From the inhibitory curves obtained, corresponding IC50 values were calculated. AF were determined by dividing the IC50 value of doxorubicin in the absence of the Betti-base, tylosin or TBN by the IC50 value of doxorubicin in their presence.
  3. Mean and s.e. values were calculated from at least four independent experiments.
Back to article page